Lantern Pharma/$LTRN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lantern Pharma
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
Ticker
$LTRN
Sector
Primary listing
Employees
16
Headquarters
Website
Lantern Pharma Metrics
BasicAdvanced
$22m
-
-$1.57
1.75
-
Price and volume
Market cap
$22m
Beta
1.75
52-week high
$5.74
52-week low
$1.11
Average daily volume
1.1m
Financial strength
Current ratio
2.4
Quick ratio
2.255
Total debt to equity
1.202
Profitability
EBITDA (TTM)
-17.961
Management effectiveness
Return on assets (TTM)
-61.39%
Return on equity (TTM)
-123.51%
Valuation
Price to book
3.41
Price to tangible book (TTM)
3.41
Price to free cash flow (TTM)
-1.376
Free cash flow yield (TTM)
-72.66%
Free cash flow per share (TTM)
-1.439
Growth
Earnings per share change (TTM)
-18.65%
3-year earnings per share growth (CAGR)
6.13%
Lantern Pharma News
AllArticlesVideos
Lantern Pharma's predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally
Business Wire·2 days ago
Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut
Business Wire·7 days ago
Emerging Data for Lantern Pharma's Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lantern Pharma stock?
Lantern Pharma (LTRN) has a market cap of $22M as of May 01, 2026.
What is the P/E ratio for Lantern Pharma stock?
The price to earnings (P/E) ratio for Lantern Pharma (LTRN) stock is 0 as of May 01, 2026.
Does Lantern Pharma stock pay dividends?
No, Lantern Pharma (LTRN) stock does not pay dividends to its shareholders as of May 01, 2026.
When is the next Lantern Pharma dividend payment date?
Lantern Pharma (LTRN) stock does not pay dividends to its shareholders.
What is the beta indicator for Lantern Pharma?
Lantern Pharma (LTRN) has a beta rating of 1.75. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.